Passage Bio reported that its gene‑replacement therapy PBFT02 produced measurable biomarker improvements in the ongoing Phase 1/2 upliFT‑D trial for frontotemporal dementia with GRN mutations. Patients treated with PBFT02 showed reduced rates of whole‑brain and frontotemporal cortex atrophy compared with natural‑history data, and plasma neurofilament light chain (NfL) levels stabilized at 12 months post‑treatment, indicating a potential disease‑modifying effect.
The company disclosed that a recent FDA Type C meeting concluded that a randomized controlled registrational trial will be required for PBFT02 to obtain approval for FTD‑GRN. This regulatory feedback shifts the program from a single‑arm design to a more rigorous, comparative study, increasing the evidentiary burden and extending the timeline for a potential Biologics License Application filing.
In response to the FDA guidance, Passage Bio has initiated a strategic review process to maximize shareholder value and has engaged Wedbush PacGrow as a financial advisor. The review will explore options such as mergers, acquisitions, asset sales, or strategic partnerships, reflecting the company’s need to address the substantial ethical, logistical, and financial challenges posed by the new trial design.
Will Chou, M.D., President and CEO, said, “the data shared today suggest that PBFT02 may slow neurodegeneration in patients with FTD‑GRN, with improvements observed in both brain atrophy and plasma neurofilament levels, two well‑established biomarkers of disease progression. Further, we continue to observe durable and robust elevations in progranulin, the target protein, and are encouraged by the emerging data from Dose 2 patients, which indicate that this lower dose level can achieve similar progranulin expression as observed with Dose 1, our higher dose.” He added, “As we look towards late‑stage development of the program, we recently completed a Type C meeting with the FDA to gain feedback on the design of a future registrational trial for PBFT02 in FTD‑GRN.”
Investors reacted negatively to the announcement, citing concerns about the increased regulatory burden and the potential for corporate restructuring. The FDA’s requirement for a randomized controlled trial signals a significant shift in the development pathway, while the strategic review introduces uncertainty about the company’s future structure and independence.
The biomarker data provide early evidence of PBFT02’s disease‑modifying potential, but the regulatory and strategic developments underscore the challenges ahead. Passage Bio will need to design a robust comparative study, secure additional funding, and navigate the strategic options identified in the review to maintain progress toward a regulatory filing. The company’s ability to manage these headwinds will shape its trajectory in the competitive gene‑therapy landscape for neurodegenerative diseases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.